Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain

In hyperglycemia, glucagon-like peptide-1 (GLP-1) lowers brain glucose concentration together with increased net blood-brain clearance and brain metabolism, but it is not known whether this effect depends on the prevailing plasma glucose (PG) concentration. In hypoglycemia, glucose depletion potentially impairs brain function. Here, we test the hypothesis that GLP-1 exacerbates the effect of hypoglycemia. To test the hypothesis, we determined glucose transport and consumption rates in seven healthy men in a randomized, double-blinded placebo-controlled cross-over experimental design. The acute effect of GLP-1 on glucose transfer in the brain was measured by positron emission tomography (PET) during a hypoglycemic clamp (3 mM plasma glucose) with 18F-fluoro-2-deoxy-glucose (FDG) as tracer of glucose. In addition, we jointly analyzed cerebrometabolic effects of GLP-1 from the present hypoglycemia study and our previous hyperglycemia study to estimate the Michaelis-Menten constants of glucose transport and metabolism. The GLP-1 treatment lowered the vascular volume of brain tissue. Loading data from hypo- to hyperglycemia into the Michaelis-Menten equation, we found increased maximum phosphorylation velocity (Vmax) in the gray matter regions of cerebral cortex, thalamus, and cerebellum, as well as increased blood-brain glucose transport capacity (Tmax) in gray matter, white matter, cortex, thalamus, and cerebellum. In hypoglycemia, GLP-1 had no effects on net glucose metabolism, brain glucose concentration, or blood-brain glucose transport. Neither hexokinase nor transporter affinities varied significantly with treatment in any region. We conclude that GLP-1 changes blood-brain glucose transfer and brain glucose metabolic rates in a PG concentration-dependent manner. One consequence is that hypoglycemia eliminates these effects of GLP-1 on brain glucose homeostasis.

• Publication year

  2013

• Venue

  Frontiers in Neuroenergetics

• Publication date

  2013-02-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3389/fnene.2013.00002PMID 23543638PMCID 3608902
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liraglutide, a Long-Acting GLP-1 Mimetic, and its Metabolite Attenuate Inflammation after Intracerebral Hemorrhage

  2012cited by this paper
• Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin‐induced diabetes detected using in vivo1H MR spectroscopy at 9.4 T

  2012cited by this paper
• Glucagon-Like Peptide-1 Decreases Intracerebral Glucose Content by Activating Hexokinase and Changing Glucose Clearance during Hyperglycemia

  2012cited by this paper
• AMP kinase regulation of sugar transport in brain capillary endothelial cells during acute metabolic stress.

  2012cited by this paper
• Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.

  2012cited by this paper
• Neuroprotective properties of GLP-1: theoretical and practical applications

  2011cited by this paper
• Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

  2011cited by this paper
• Differences between long-acting insulins for the treatment of type 2 diabetes

  2010cited by this paper
• The perivascular astroglial sheath provides a complete covering of the brain microvessels: An electron microscopic 3D reconstruction

  2010cited by this paper
• AMPK in the brain: its roles in energy balance and neuroprotection

  2009cited by this paper
• Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?

  2009cited by this paper
• Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

  2009cited by this paper
• Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans

  2008cited by this paper
• Supply and Demand in Cerebral Energy Metabolism: The Role of Nutrient Transporters

  2007influential reference
• The physiology of glucagon-like peptide 1.

  2007cited by this paper
• Human Cerebral Blood Flow and Metabolism in Acute Insulin-Induced Hypoglycemia

  2005cited by this paper
• Differential changes in brain glucose metabolism during hypoglycaemia accompany loss of hypoglycaemia awareness in men with type 1 diabetes mellitus. An [11C]-3-O-methyl-d-glucose PET study

  2005cited by this paper
• Neurobarrier Coupling in the Brain: A Partner of Neurovascular and Neurometabolic Coupling?

  2005cited by this paper
• New ways in which GLP-1 can regulate glucose homeostasis.

  2005cited by this paper
• Diverse causes of hypoglycemia-associated autonomic failure in diabetes.

  2004cited by this paper
• Extrapancreatic Effects of GIP and GLP-1

  2004cited by this paper
• Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.

  2004cited by this paper
• Cerebral glucose metabolism in diabetes mellitus.

  2004cited by this paper
• Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

  2002cited by this paper
• Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia.

  2001cited by this paper
• Blood-brain barrier transport and brain metabolism of glucose during acute hyperglycemia in humans.

  2001cited by this paper
• Effects of oral glucose on systemic glucose metabolism during hyperinsulinemic hypoglycemia in normal man.

  2000cited by this paper
• Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

  1999cited by this paper
• No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Calculation of the FDG Lumped Constant by Simultaneous Measurements of Global Glucose and FDG Metabolism in Humans

  1998influential reference
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Lack of preservation of higher brain function during hypoglycaemia in patients with intensively-treated IDDM

  1995cited by this paper
• Adaptation in brain glucose uptake following recurrent hypoglycemia.

  1994cited by this paper
• Facilitated transport of glucose from blood to brain in man and the effect of moderate hypoglycaemia on cerebral glucose utilization

  1991cited by this paper
• Michaelis-Menten Constraints Improved Cerebral Glucose Metabolism and Regional Lumped Constant Measurements with [18F]Fluorodeoxyglucose

  1990cited by this paper
• Comparative Regional Analysis of 2-Fluorodeoxyglucose and Methylglucose Uptake in Brain of Four Stroke Patients. With Special Reference to the Regional Estimation of the Lumped Constant

  1985cited by this paper
• Estimates of Michaelis-Menten Constants for the Two Membranes of the Brain Endothelium

  1984cited by this paper
• Brain metabolism: a perspective from the blood-brain barrier.

  1983cited by this paper
• Modulation of substrate transport to the brain

  1983cited by this paper
• Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination.

  1982cited by this paper
• High‐ and Low‐Affinity Transport of D‐Glucose from Blood to Brain

  1981cited by this paper
• Blood-brain glucose transfer: repression in chronic hyperglycemia.

  1981cited by this paper
• Facilitated transfer of glucose from blood into brain tissue.

  1965influential reference

• Incretins and the cardiovascular system: bridging digestion with metabolism.

  2025cites this paper
• Insights into therapeutic approaches for the treatment of neurodegenerative diseases targeting metabolic syndrome

  2025cites this paper
• Targeting Brain Connectivity in Alzheimer's Disease with Repurposed Drugs.

  2025cites this paper
• Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities.

  2022cites this paper
• Brain Glucose Transporters: Role in Pathogenesis and Potential Targets for the Treatment of Alzheimer’s Disease

  2021cites this paper
• Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon‐like peptide‐1 receptor agonists

  2021cites this paper
• Stomach 'tastes' the food and adjusts its emptying: A neurophysiological hypothesis (Review).

  2020cites this paper
• Disturbances in brain energy metabolism in insulin resistance and diabetes and Alzheimer's disease - Learnings from brain imaging biomarkers.

  2020cites this paper
• Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation

  2020cites this paper
• Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease

  2019cites this paper
• Neuromodulatory effects of anti-diabetes medications: a mechanistic review.

  2019cites this paper
• Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon‐like peptide 1 receptor agonists?

  2018cites this paper
• Linked Hexokinase and Glucose-6-Phosphatase Activities Reflect Grade of Ovarian Malignancy

  2018cites this paper
• Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment

  2017cites this paper
• The effects of incretin hormones on cerebral glucose metabolism in health and disease

  2017cites this paper
• Cerebral Blood Flow and Aβ-Amyloid Estimates by WARM Analysis of [11C]PiB Uptake Distinguish among and between Neurodegenerative Disorders and Aging

  2017cites this paper
• In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

  2016cites this paper
• Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study

  2016cites this paper
• Improving healthspan via changes in gut microbiota and fermentation

  2015cites this paper
• Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation andNeuroprotection

  2015cites this paper
• Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury

  2015cites this paper
• Energy Metabolism, Adult Neurogenesis and their Possible Roles in Alzheimer's Disease: A Brief Overview.

  2015cites this paper
• Influence of GLP-1 on Myocardial Glucose Metabolism in Healthy Men during Normo- or Hypoglycemia

  2014cites this paper
• Positron Emission Tomography of Brain Glucose Metabolism with [ 18 F]Fluorodeoxyglucose in Humans

  2014cites this paper
• Regulation of glucose homeostasis by GLP-1.

  2014cites this paper
• At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.

  2014cites this paper
• Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited

  2014cites this paper
• Neuroendocrine link between stress, depression and diabetes

  2013cites this paper